Latest News and Press Releases
Want to stay updated on the latest news?
-
Implementation of a series of measures to promote employee safety and support local community Publication of top-line results of the Phase IIb NATIVE clinical trial for lanifibranor in NASH on...
-
La dernière visite du dernier patient a eu lieu aux États-Unis le 16 mars 2020 La publication des principaux résultats de l’étude est prévue pour juin 2020 Daix (France), le 17 mars 2020 –...
-
Last patient last visit took place in the United States on March 16, 2020 Publication of study head-line results expected for June 2020 Daix (France), March 17, 2020 – Inventiva (Euronext:...
-
► Lanifibranor : Confirmation de la publication des résultats de l’étude clinique de Phase IIb NATIVE évaluant lanifibranor dans la NASH au S1 2020 suite à la finalisation du recrutement des...
-
2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
► Lanifibranor: Confirmation of the publication of the results of the Phase IIb NATIVE clinical study evaluating lanifibranor in NASH in H1 2020 following the completion of patient recruitment ...
-
Daix (France), le 19 février 2020 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement...
-
Daix (France), February 19, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of...
-
Daix (France), le 10 février 2020 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement...
-
Daix (France), February 10, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of...
-
New financing will enable the Company to extend its cash runway to the end of Q2 2021 Capital raised at the closing price of February 6, 2020 without discount Capital increase subscribed by BVF...